Cellectis (CLLS) Cash from Investing Activities Growth (1y) (2016 - 2026)
Powered by 
Analysis
Cellectis (CLLS) Cash from Investing Activities Growth (1y) (2016 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 90.55% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 91.53% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -41.67% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.90% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -157.08% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 26.37% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -89.24% |
| 10 | Cellectis | 321.90 Mn | 155.05 Mn | - | 135.50% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 135.50% |
| Mar 31, 2026 | -245.99% |
| Dec 31, 2025 | 234.75% |
| Sep 30, 2025 | -115.41% |
| Jun 30, 2025 | 50.47% |
| Mar 31, 2025 | 305.90% |
| Dec 31, 2024 | -22.03% |
| Sep 30, 2024 | 7,544.33% |
| Jun 30, 2024 | -5,916.34% |
| Mar 31, 2024 | -1,642.11% |
| Dec 31, 2023 | -4,707.39% |
| Sep 30, 2023 | -159.29% |
| Jun 30, 2023 | 4.43% |
| Mar 31, 2023 | 119.39% |
| Dec 31, 2022 | 97.46% |
| Sep 30, 2022 | 120.59% |
| Jun 30, 2022 | -119.21% |
| Mar 31, 2022 | -323.45% |
| Dec 31, 2021 | -211.15% |
| Sep 30, 2021 | -207.90% |